TABLE 4.
Logistic regression model for genetic variants in PTGS1 and NOS3 genes in low-dose aspirin and nonsteroidal anti-inflammatory drug users, and risk of upper gastrointestinal bleeding secondary to complicated peptic disease.
| Variable | Logistic regression model | |||
|---|---|---|---|---|
| N case/control | Insert method | |||
| OR | CI 95% | p-value | ||
| LDA users a | ||||
| PTGS1 gene | ||||
| rs1330344 (C > T) | ||||
| CT | 22/31 | 5.76 | 2.50–13.23 | <0.001 b |
| TT | 26/52 | 2.71 | 1.27–5.75 | 0.009 b |
| CT + TT genotypes | 48/83 | 3.73 | 2.00–6.95 | <0.001 b |
| rs10306114 (A > G) | ||||
| AG | 8/10 | 3.95 | 1.19–13.07 | 0.024 b |
| GG | 1/0 | — | — | — c |
| AG + GG genotypes | 9/10 | 4.15 | 1.28–13.50 | 0.018 b |
| rs3842787 (C > T) | ||||
| CT | 10/15 | 2.42 | 0.81–7.21 | 0.110 |
| TT | 1/0 | — | — | — c |
| CT + TT genotypes | 11/15 | 2.56 | 0.88–7.44 | 0.084 |
| rs5788 (C > A) | ||||
| CA | 18/33 | 1.83 | 0.76–4.39 | 0.176 |
| AA | 3/8 | 1.58 | 0.33–7.42 | 0.558 |
| CA + AA genotypes | 21/41 | 1.77 | 0.81–3.86 | 0.151 |
| NOS3 gene | ||||
| rs2070744 (C > T) | ||||
| CT | 27/39 | 4.00 | 1.84–8.71 | <0.001 b |
| TT | 16/30 | 3.20 | 1.29–7.92 | 0.012 b |
| CT + TT genotypes | 43/69 | 3.66 | 1.90–7.04 | <0.001 b |
| rs1799983 (G > T) | ||||
| GT | 26/29 | 4.54 | 2.10–9.82 | <0.001 b |
| TT | 2/9 | 2.15 | 0.30–15.43 | 0.445 |
| GT + TT genotypes | 28/38 | 4.21 | 2.00–8.89 | <0.001 b |
| NSAID users d | ||||
| PTGS1 gene | ||||
| rs1330344 (C > T) | ||||
| CT | 17/30 | 5.74 | 2.56–12.85 | 0.024 b |
| TT | 15/35 | 2.47 | 1.11–5.50 | 0.027 b |
| CT + TT genotypes | 32/65 | 3.70 | 2.05–6.66 | <0.001 b |
| rs10306114 (A > G) | ||||
| AG | 5/8 | 5.69 | 1.46–22—07 | 0.012 b |
| GG | 0/0 | — | — | — c |
| AG + GG genotypes | — | — | — | — |
| rs3842787 (C > T) | ||||
| CT | 8/13 | 5.69 | 1.86–17.39 | 0.002 b |
| TT | 0/0 | — | — | — c |
| CT + TT genotypes | — | — | — | — |
| rs5788 (C > A) | ||||
| CA | 12/23 | 2.38 | 0.98–5.77 | 0.055 |
| AA | 4/5 | 4.21 | 0.84–21.03 | 0.079 |
| CA + AA genotypes | 16/28 | 2.71 | 1.25–5.88 | 0.012 b |
| NOS3 gene | ||||
| rs2070744 (C > T) | ||||
| CT | 15/35 | 2.50 | 1.13–5.54 | 0.024 b |
| TT | 16/15 | 10.99 | 4.25–28.38 | <0.001 |
| CT + TT genotypes | 31/50 | 4.43 | 2.37–8.26 | <0.001 b |
| rs1799983 (G > T) | ||||
| GT | 17/23 | 4.57 | 2.01–10.37 | <0.001 b |
| TT | 5/4 | 37.07 | 5.67–242.21 | <0.001 b |
| GT + TT genotypes | 22/27 | 6.53 | 3.10–13.74 | <0.001 b |
N, number of participants of case/control groups; OR, odds ratio; CI 95%, confidence interval 95%; LDA, low-dose aspirin; NSAIDs, nonsteroidal anti-inflammatory drugs.
Analysis adjusted to ethnicity; body mass index; history of ulcer, bleeding and dyspepsia; cardiovascular, blood, and respiratory diseases; Helicobacter pylori serology; reliability of the interview; use of oral anticoagulants and nonsteroidal anti-inflammatory drugs; smoking habit; alcohol intake; and amount of coffee consumption per day.
Statistical significance.
It was not possible to conduct the analysis with the homozygous category for variant allele due to the absence of participants or reduced sample size.
Analysis adjusted to ethnicity; body mass index; history of ulcer, bleeding and dyspepsia; cardiovascular, blood and respiratory disease; Helicobacter pylori serology; reliability of the interview; use of oral anticoagulants and low-dose aspirin; smoking habit; alcohol intake; and amount of coffee consumption per day.
The category of reference for genetic variants is the wild phenotype.